SuperworthEikon Therapeutics EPS EIKN
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$1.63
Eikon Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$1.63.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$1.63 | n/a | |
| Q1 FY26 | −$2.46 | n/a | |
| Q2 FY25 | −$36.94 | n/a | |
| Q1 FY25 | −$26.91 | n/a |
Against its peers
Companies in Biotechnology nearest Eikon Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| EIKNEikon Therapeutics | n/m | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Eikon Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.